Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
J Clin Med ; 11(21)2022 Oct 28.
Artigo em Inglês | MEDLINE | ID: mdl-36362589

RESUMO

Functional gastrointestinal disorders (FGIDs), including irritable bowel syndrome (IBS), are frequently handled by self-management with over-the-counter (OTC) products such as hyoscine butylbromide (HBB), alone or in combination with paracetamol, and natural products such as peppermint oil. To obtain real-world information, we have performed an anonymous pharmacy-based patient survey among 1686 users of HBB, HBB + paracetamol, and peppermint oil. Based on the distinct but overlapping indications for the three OTC products, multiple logistic regression was applied to compare them in users reporting gastrointestinal cramps and pain, bloating, flatulence, or IBS as cardinal symptoms. All three treatments reduced symptoms and associated impairments of work/daily chores, leisure activities, and sleep by approximately 50%. Based on the four cardinal symptoms and the four dependent continuous variables of interest (change in intensity of symptoms and of the three impairment domains) a total of 16 logistic regression models were applied. HBB, HBB + paracetamol, and peppermint oil had similar reported overall effectiveness in those models. Gender, age, baseline symptom severity, and impairment in one of three domains had small and inconsistent effects on perceived treatment success. We provide evidence that HBB, HBB + paracetamol, and peppermint oil have comparable effectiveness in their approved indications under real-world conditions in an OTC setting.

2.
Front Med (Lausanne) ; 7: 276, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32656217

RESUMO

Enterococcus faecium SF68® (SF68) is a licensed pharmaceutical for treatment and prevention of diarrhea in Austria, Italy and Switzerland. However, as for other probiotics, evidence for its efficacy is based on small to medium-sized studies. Four unpublished studies on the treatment of acute diarrhea and the prevention of antibiotic-associated diarrhea were analyzed: one randomized, double blind, placebo-controlled trial (RCT) for treatment (n = 1,143), one open-label study for treatment (n = 5,093), one RCT for prevention (n = 1,397) and one open-label study for prevention (n = 4,340). Patients in the treatment-arm and the open-label studies received SF68 (b.i.d. for the prevention studies, t.i.d. for the treatment trials) for 7 days. Primary end points were time to resolution of diarrhea (treatment) and percentage of development of diarrhea (prevention). The primary endpoint of the treatment study was met with a decreased time to resolution of diarrhea in SF68-treated patients compared to controls (median 3 vs. 4 days, p < 0.001). Time to resolution of secondary symptoms was also significantly reduced. Preventive treatment with SF68 was more effective than placebo with development of diarrhea in 8.6 vs. 16.2% (p < 0.001). Results from the open-label studies were consistent with the RCTs. The incidence of adverse events were low (1.1 and 1.4% in the RCT and 4.7 and 7.4% in the open-label studies). SF68 is effective and safe in the treatment of acute diarrhea and prevention of antibiotic-associated diarrhea.

3.
Adv Ther ; 36(3): 597-607, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30758744

RESUMO

INTRODUCTION: Caffeine is used as an adjuvant in analgesic combinations to enhance their efficacy. The present study aimed to determine the effect of caffeine on the pharmacokinetics of acetylsalicylic acid (ASA) and paracetamol when used as a fixed-dose ASA/paracetamol/caffeine combination. METHODS: In this single-centre, two-way, cross-over phase I study, volunteers fasted overnight (≥ 12 h) and randomly received single oral doses of 250 mg ASA/200 mg paracetamol (reference) or 250 mg ASA/200 mg paracetamol/50 mg caffeine (test). Blood samples were collected before and up to 24 h after dosing. The primary end points were the area under the concentration-time curve from zero to infinity (AUC0-∞) and maximum plasma concentration (Cmax) for ASA, salicylic acid (SA) and paracetamol from the two combinations. The main secondary end points were AUC0-∞ and Cmax of caffeine and time to reach Cmax (tmax) of all drugs. RESULTS: Eighteen healthy male volunteers (32.5 ± 10.5 years) participated in the study. The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively). The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively. The medians of tmax for ASA, SA and paracetamol were similar between the two groups. The point estimates for the ratios of AUC0-∞ and Cmax for test versus reference regarding ASA, SA and paracetamol were within the predefined equivalence limits. The two treatments were well tolerated. CONCLUSION: Caffeine did not affect the pharmacokinetics of ASA and paracetamol when used as an adjuvant in ASA/paracetamol fixed-dose combination under fasting conditions, suggesting that caffeine enhances the analgesic efficacy of these drugs by pharmacodynamic rather than pharmacokinetic interactions. FUNDING: Sanofi-Aventis Deutschland GmbH.


Assuntos
Acetaminofen/farmacocinética , Analgésicos/farmacocinética , Aspirina/farmacocinética , Cafeína/farmacologia , Acetaminofen/farmacologia , Adulto , Área Sob a Curva , Aspirina/farmacologia , Estudos Cross-Over , Combinação de Medicamentos , Jejum , Voluntários Saudáveis , Humanos , Masculino , Adulto Jovem
4.
Z Gastroenterol ; 55(3): 260-266, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28288501

RESUMO

Background Abdominal pain, cramping, and discomfort (APCD) are experienced by up to 30 % of adults in Europe. Objective To assess the impact of APCD on quality of life (QoL) and to investigate the effectiveness, tolerability, and impact on QoL of hyoscine butylbromide (HBB, Buscopan®) compared with STW 5 (Iberogast®) or analgesics in women with APCD. Methods An internet-based observational pilot study was conducted in Germany in women who had predominantly used HBB, STW 5, or analgesics (n = 240 per treatment) to treat APCD. This online survey included questions on QoL, effectiveness, and tolerability. Results A total of 720 completed questionnaires was evaluated. APCD had a major impact on QoL, with 96 % of women reporting that daily activities were disrupted at least sometimes, and 44 % at least often. Other aspects of QoL, such as quality of work, eating habits, and social activities, were also affected in most women. After taking their medication of choice, 91 % of women in the HBB group reported they could "very often" or "often" continue with their daily activities, compared with 84 % and 85 % in the STW 5 and analgesic groups, respectively (p < 0.05 for both comparisons). HBB was perceived to be the "best solution" to overcome APCD symptoms "very often" or "often" by more women (86 %) than STW 5 (75 %) and analgesics (74 %) (p < 0.05 for both comparisons). Conclusion Women with APCD have impaired QoL. All treatments were considered effective by the majority of participants. Compared with STW 5 or analgesics, HBB was reported to facilitate return to daily activities more frequently.


Assuntos
Dor Abdominal/tratamento farmacológico , Dor Abdominal/psicologia , Analgésicos/administração & dosagem , Brometo de Butilescopolamônio/administração & dosagem , Fármacos Gastrointestinais/administração & dosagem , Extratos Vegetais/administração & dosagem , Qualidade de Vida/psicologia , Dor Abdominal/epidemiologia , Adolescente , Adulto , Idoso , Cólica/tratamento farmacológico , Cólica/epidemiologia , Cólica/psicologia , Feminino , Alemanha/epidemiologia , Humanos , Internet/estatística & dados numéricos , Pessoa de Meia-Idade , Parassimpatolíticos/administração & dosagem , Projetos Piloto , Prevalência , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento , Saúde da Mulher/estatística & dados numéricos , Adulto Jovem
5.
BMC Psychiatry ; 11: 150, 2011 Sep 20.
Artigo em Inglês | MEDLINE | ID: mdl-21933428

RESUMO

BACKGROUND: To investigate the association of the change of painful physical symptoms (PPS) after 4 weeks, with the 6-month treatment outcomes of depressive symptoms in patients treated with duloxetine in clinical practice. METHODS: Multicenter, prospective, 6-month, non-interventional study in adult outpatients with a depressive episode and starting treatment with duloxetine. Depression severity was assessed by the clinician (Inventory for Depressive Symptomatology [IDS-C]) and patient (Kurz-Skala Stimmung/Aktivierung [KUSTA]). Somatic symptoms and PPS were assessed using the patient-rated Somatic Symptom Inventory (SSI) and visual analog scales (VAS) for pain items. Association of change in PPS with outcomes of depressive symptoms was analyzed based on mean KUSTA scores (mean of items mood, activity, tension/relaxation, sleep) and achievement of a 50% reduction in the total IDS-C score after 6 months using linear and logistic regression models, respectively. RESULTS: Of the 4,517 patients enrolled (mean age: 52.2 years, 71.8% female), 3,320 patients (73.5%) completed the study. 80% of the patients had moderate to severe overall pain (VAS > 30 mm) at baseline. A 50% VAS overall pain reduction after 4 weeks was associated with a 13.32 points higher mean KUSTA score after 6 months, and a 50% pain reduction after 2 weeks with a 6.33 points improvement. No unexpected safety signals were detected in this naturalistic study. CONCLUSION: Pain reduction after 2 and 4 weeks can be used to estimate outcomes of long-term treatment with duloxetine. PPS associated with depression have a potential role in predicting remission of depressive symptoms in clinical practice.


Assuntos
Antidepressivos/uso terapêutico , Depressão/tratamento farmacológico , Dor/tratamento farmacológico , Tiofenos/uso terapêutico , Antidepressivos/efeitos adversos , Depressão/complicações , Cloridrato de Duloxetina , Feminino , Humanos , Classificação Internacional de Doenças/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Pacientes Ambulatoriais/psicologia , Dor/complicações , Medição da Dor/efeitos dos fármacos , Medição da Dor/métodos , Estudos Prospectivos , Índice de Gravidade de Doença , Tiofenos/efeitos adversos
6.
Artigo em Inglês | MEDLINE | ID: mdl-12505788

RESUMO

A fully automated chromatographic method including on-line blood serum or plasma clean-up, isocratic high-performance liquid chromatography (HPLC) and spectrophotometric detection was developed for quantitative analysis of the new antipsychotic drug amisulpride. After injection of serum or plasma onto the HPLC system and clean-up on a pre-column (10x4.0 mm I.D.) filled with Silica CN 20 micrometer (pore size 10 nm) by an eluent consisting of 8% acetonitrile in deionized water, the chromatographic separation was performed on Lichrospher CN (5 micrometer; 250x4.6 mm I.D.) by an eluent consisting of 50% acetonitrile and 50% aqueous potassium phosphate buffer (0.008 M, pH 6.4). The UV detector was set at 254 nm. The limit of quantification was about 10 microgram/l. The method revealed linearity between 10 and 600 microgram/l (correlation coefficients R(2)>0.9996). The inter-assay reproducibility (coefficient of variation) of quality control samples was between 2.8 and 11.3%. Inaccuracy was between -0.6 and +9.1%. The performance of daily calibration standards revealed an imprecision always below 15% and maximum inaccuracy of 7.7%. The method can be applied to therapeutic drug monitoring as well as pharmacokinetic studies of amisulpride.


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Espectrofotometria/métodos , Sulpirida/análogos & derivados , Sulpirida/sangue , Amissulprida , Humanos , Padrões de Referência
7.
J Clin Psychopharmacol ; 22(5): 502-6, 2002 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12352274

RESUMO

Olanzapine is a substrate of the cytochrome P450 enzyme (CYP) 1A2. In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia. Eight patients had been treated for at least 3 months with 10 to 20 mg/day olanzapine. Fluvoxamine (100 mg/day) was added (week 0) to the olanzapine treatment and continued for 8 weeks. Concentrations of olanzapine and its metabolite N-desmethylolanzapine and of fluvoxamine were analyzed at weeks 0, 1, 4, and 8. Addition of fluvoxamine resulted in a 12% to 112% ( < 0.01) increase of olanzapine from 31 +/- SD 15 ng/mL (week 0) to 56 +/- 31 ng/mL (week 8) in all patients. N-desmethylolanzapine concentrations were not significantly changed ( > 0.05). Fluvoxamine concentrations were 48 +/- 26 ng/mL on week 1 and 83 +/- 47 ng/mL on week 8. It is concluded that fluvoxamine affects olanzapine degradation and thus increases olanzapine concentrations. Although the combination was well tolerated in this sample and the negative symptom response appeared to be favorable in at least five patients, the combination therapy of olanzapine and fluvoxamine should be used cautiously and should be controlled by therapeutic drug monitoring to avoid olanzapine-induced side effects or intoxications.


Assuntos
Interações Medicamentosas , Fluvoxamina/farmacocinética , Fluvoxamina/uso terapêutico , Pirenzepina/análogos & derivados , Pirenzepina/farmacocinética , Pirenzepina/uso terapêutico , Esquizofrenia/tratamento farmacológico , Inibidores Seletivos de Recaptação de Serotonina/farmacocinética , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Adulto , Benzodiazepinas , Quimioterapia Adjuvante , Doença Crônica , Feminino , Fluvoxamina/administração & dosagem , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Pirenzepina/administração & dosagem , Estudos Prospectivos , Inibidores Seletivos de Recaptação de Serotonina/administração & dosagem , Fatores de Tempo
8.
Pharm Res ; 19(7): 1034-7, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12180536

RESUMO

PURPOSE: This study was conducted to identify the cytochrome P450s (CYPs) responsible for the metabolism of the cis- and trans-isomers of the tricyclic antidepressant doxepin to its pharmacologically active N-desmethylmetabolite by in vitro techniques. METHODS: The doxepin N-demethylation was studied by means of pooled human liver microsomes and chemical inhibitors, recombinant human (rh)-CYPs, and geno- and phenotyped human liver microsomes. RESULTS: The N-demethylation of both isomers was inhibited most prominently by tranylcypromine (CYP2C19) to more than 50%. Furafylline (CYP1A2) and sulfaphenazole (CYP2C9) inhibited the N-demethylation to a lesser extent while quinidine (CYP2D6) or troleandomycine (CYP3A4) had no effect. Rh-CYP2C19, -CYP1A2, and -CYP2C9 were able to N-demethylate cis- and trans-doxepin. Only traces of trans-desmethyldoxepin were detectable when CYP3A4 was used. The maximum velocity in the cis- and transdoxepin N-demethylation was significantly (P < 0.05) lower in microsomes with low CYP2C19 activity (345 +/- 44 and 508 +/- 75 pmol/min/ mg protein, respectively) compared to those with high CYP2C19 activity (779 +/- 132 and 1,189 +/- 134 pmollmin/mg). CONCLUSION: The present study demonstrates a significant contribution of the polymorphic CYP2C19 to the N-demethylation of doxepin. CYP2C9 and CYP1A2 play a minor role and CYP3A4 does not contribute substantially.


Assuntos
Hidrocarboneto de Aril Hidroxilases/metabolismo , Doxepina/análogos & derivados , Doxepina/química , Doxepina/metabolismo , Microssomos Hepáticos/enzimologia , Oxigenases de Função Mista/metabolismo , Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Catálise , Citocromo P-450 CYP2C19 , Humanos , Isoenzimas/antagonistas & inibidores , Isoenzimas/metabolismo , Isotiocianatos/farmacologia , Oxigenases de Função Mista/antagonistas & inibidores , Tranilcipromina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...